Concepedia

Safety and efficacy of autologous hematopoietic stem‐cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis

Alice Mariottini, Chiara Innocenti, Benedetta Forci, Eliana Magnani, Claudia Mechi, Alessandro Barilaro, Riccardo Nistri, Arianna Fani, Riccardo Saccardi, Luca Massacesi,

European Journal of Neurology · 2018 · 28 citations · 9 references

DOI

Abstract

These data suggest that an aggressive therapy should be established after NTZ with the shortest possible wash-out period. aHSCT after 6 months from NTZ withdrawal appears to be safe.

References

9

Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study

A. Kazis, K. Kapinas, Ioanna Sakellari et al. · Bone Marrow Transplantation · 1997 · 408 citations

, , +13

Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases

Dominique Farge, Myriam Labopin, Alan Tyndall et al. · Haematologica · 2009 · 355 citations · Full text

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

Paul O’Connor, Andrew Goodman, Ludwig Kappos et al. · Neurology · 2011 · 295 citations

T cell repertoire following autologous stem cell transplantation for multiple sclerosis

Paolo A. Muraro, Harlan Robins, Sachin Malhotra et al. · Journal of Clinical Investigation · 2014 · 260 citations · Full text

, , +25

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

Peter Alping, Thomas Frisell, Lenka Novakova et al. · Annals of Neurology · 2016 · 224 citations